Qiagen to offer $220M of notes
Netherlands-based Qiagen has announced plans to offer $220.0 million of senior convertible notes due 2026 in minimum denominations of $100,000 to institutional investors outside the US in reliance on Regulation S under the Securities Act of 1933. The company also plans to grant the initial purchasers of the notes an option to buy up to an additional $30.0 million aggregate principal amount.
Qiagen says it believes that the convertible bond market currently offers attractive financing opportunities. The company plans to use the proceeds of this offering to optimize the structure of its balance sheet (which may include the repayment of existing debt), to finance future acquisitions and for general corporate purposes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze